New study aims to sharpen prognosis tools for rare blood cancer
NCT ID NCT05911802
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 500 people with Waldenström macroglobulinemia, a rare blood cancer, to check how well current scoring systems predict survival and treatment response. Researchers will track patients over time, including those without symptoms, to refine these tools. The goal is to help doctors make better treatment decisions and design faster clinical trials for new therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors better predict disease progression and tailor treatments for Waldenström patients, potentially improving survival and quality of life.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly provide new therapies. Results may not apply to all patient groups or lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMIENS - CH Amiens Picardie Site Sud
NOT_YET_RECRUITINGAmiens, 80054, France
Contact Email: •••••@•••••
-
APHP - Hôpital Pitié Salpêtrière - Hématologie
NOT_YET_RECRUITINGParis, 75651, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Angers Chu
NOT_YET_RECRUITINGAngers, 49933, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clermont-Ferrand - Chu Estaing
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact Email: •••••@•••••
-
Institut Bergonie
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmette
NOT_YET_RECRUITINGMarseille, 130009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
LENS - GHT Artois
NOT_YET_RECRUITINGLens, 62300, France
Contact Email: •••••@•••••
-
LIBOURNE - Hôpital Robert Boulin
NOT_YET_RECRUITINGLibourne, 33505, France
Contact Email: •••••@•••••
-
LILLE GHICL - Hôpital Saint Vincent de Paul
RECRUITINGLille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Le Mans CH
NOT_YET_RECRUITINGLe Mans, France
Contact Email: •••••@•••••
-
POITIERS - Hématologie et Thérapie Cellulaire
NOT_YET_RECRUITINGPoitiers, 86021, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Reims Chu
NOT_YET_RECRUITINGReims, 51092, France
Contact Email: •••••@•••••
-
Strasbourg - Icans
NOT_YET_RECRUITINGStrasbourg, 67033, France
Contact Email: •••••@•••••
-
Toulouse - IUCT Oncopole - Service d'Hématologie
NOT_YET_RECRUITINGToulouse, 31059, France
Contact Email: •••••@•••••
-
VERSAILLES - Hôpital André Mignot
NOT_YET_RECRUITINGVersailles, France
Contact